Four life sciences researchers at the University of Pennsylvania, University of Delaware, Children’s Hospital of Philadelphia and Temple University earned a total of $700,000 from the University City Science Center as part of the organization’s QED Program, which pairs academic researchers with the funds they need to give their ideas a test run and ease the path to commercialization.
It’s the 11th iteration of QED — which stands for the Latin phrase quod erat demonstrandum, or “proven as demonstrated.” Since its inception in 2009, it has offered awarded $7 million to 128 projects, leading to $22 million in follow-on funding.
Each project is also matched with a business advisor to “evaluate a go-to-market strategy and prepare a commercialization funding plan for each technology,” per a press release.
Congrats to researchers at @PennPCI @templemedschool @ChildrensPhila & @UDelaware on receiving QED awards on the proof-of-concept program's 10th anniversary. https://t.co/pby2EJHibq pic.twitter.com/J5sr6G8Qav
— Science Center (@UCScienceCenter) February 6, 2019
The latest awardees were selected from a pool of 50 applicants from 12 academic and research institutions in Pennsylvania, New Jersey and Delaware.
“Over the last 10 years, we’ve worked with over 100 researchers developing promising technologies in an effort to bridge the divide between basic research and technology commercialization,” said Science Center President and CEO Steve Zarrilli in a statement. “Thirty-eight projects funded and 10 licensing deals later, we’re proud of the platform we’ve developed and the impact we’ve seen as a result of the program.”
Meet the selected academics and the projects they will be taking on, in the Science Center’s words:
- Dr. Ahad Behboodi, University of Delaware — Developing a compact and soft mechanized brace for people with ankle control deficits, to help them walk more easily and longer
- Dr. Jacob S. Brenner, University of Pennsylvania — Developing a vest that relieves shortness of breath in chronic obstructive pulmonary disease (COPD) patients
- Dr. John M. Maris, Children’s Hospital of Philadelphia — Developing a T-cell based immunotherapeutic treatment for children with neuroblastoma
- Dr. Servio H. Ramirez, Lewis Katz School of Medicine at Temple University — Advancing the development of a blood test for the evaluation of traumatic brain injury
Before you go...
Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.
3 ways to support our work:- Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
- Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
- Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!